Kornimate/medical-research-clean huggingface dataset:
randomised comparison of 2 cold snare polypectomy techniques

Conditions: Bowel Cancer

Summary: different modalities are employed to remove small colonic polyps which potentially harbour a cancer risk. but, they can all vary in their completeness of removal, safety and the histological quality and the gold standard technique has yet to be defined. a novel suction pseudopolyp technique has been described by patullo et al and in their prospective study, 126 polyps measuring less than 10mm flat or sessile were removed by this method with 100% complete endoscopic resection and without any immediate or delayed complications. the aim of the investigators study is to compare this technique with the standard cold snare technique. patients attending for a routine colonoscopy and found to have polyps measuring 37mm in size will be eligible and they will be randomised to the polypectomy technique. patient demographics and polyp characteristics will be recorded. the primary outcome measured will be the macroscopic resection rate. the secondary outcome measures are abdominal pain, tenderness, bleeding and fever.


Eligibility criteria:
inclusion criteria: * all patients with small polyps 3-7 mm in size, flat or sessile found during colonoscopy exclusion criteria: * patients are less than 18 years old * pregnant * inadequate bowel preparation * on anticoagulants or clopidogrel
compare blood sugar level between lantus in the morning and other insulins in type 1 diabetes adolescents

Conditions: Diabetes Mellitus

Summary: the purpose of the study is to compare the effect in blood sugar control between lantus and twice daily intermediate acting insulins (nph or lente) when used as the basal insulin in a multiple daily injection setting with fast acting insulin (lispro)


Eligibility criteria:
inclusion criteria: * type 1 diabetes treated with insulin only for at least 1 year, * with a tanner stage of ≥ 2, * had evidence of decreased insulin secretory capacity (fasting c-peptide concentration ≤0.5 mmol/l) and 7.0%≤a1c≤9.5% at screening. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
intravenous proton pump inhibitor for peptic ulcer bleeding

Conditions: Peptic Ulcer Hemorrhage

Summary: a large dose of ppi is effective in preventing peptic ulcer rebleeding. the investigators hypothesize that 40 mg/q6h pantoloc is equivalent to 8mg/h pantoloc in preventing rebleeding.

a bleeding peptic ulcer remains a serious medical problem with significant morbidity and mortality. endoscopic therapy significantly reduces further bleeding, surgery, and mortality in patients with bleeding peptic ulcers and is now recommended as the first hemostatic modality for these patients. in the past few years, adjuvant use of a high-dose proton pump inhibitor (ppi) after endoscopic therapy has been endorsed in some studies, two consensus statements and two meta-analysis. in our previous experience, we used omeprazole 160 mg /day infusion instead of 8 mg/h in these patients and obtained a good result . the objectives of this study are to assess the outcomes of two different regimens of high dose of intravenous pantoprazole after endoscopic therapy in patients with peptic ulcer bleeding.

Eligibility criteria:
inclusion criteria: * patients were accepted for endoscopic therapy if a peptic ulcer with active bleeding, a non-bleeding visible vessel (nbvv) or an adherent blood clot at the ulcer base was observed within 24 hours of hospital admission. exclusion criteria: * if patients were pregnant * did not obtain initial hemostasis with endoscopic injection of epinephrine * did not give written informed consent * had bleeding tendency (platelet count \< 50×109/l, serum prothrombin \< 30% of normal, or were taking anticoagulants), uremia.

Keywords: shock peptic ulcer bleeding rebleeding
treatment of primary generalized tonic-clonic seizures with an investigational new drug

Conditions: Epilepsy, Tonic-Clonic

Summary: the purpose of this study is to evaluate the effectiveness and safety of an investigational new drug for supplemental therapy in subjects with primary generalized tonic-clonic (pgtc) seizures.


Eligibility criteria:
inclusion criteria: * weigh at least 13kg. * have a confident diagnosis of epilepsy with primary generalized tonic-clonic (pgtc) seizures with or without other generalized seizure types. * currently being treated with an antiepileptic drug(s) (aed). * benzodiazepines are allowed with some frequency restrictions. * vagus nerve stimulation is allowed if in place for at least 6 months prior to starting the study with no changes to the settings having occured during the month immediately prior to starting the study, and if no changes will occur during all phases of the study. * history of primary generalized tonic-clonic seizures with no focal onset. * have at least 1 primary generalized tonic-clonic (pgtc) seizure during the 8 consecutive weeks prior to the baseline period of the study. * have at least 3 pgtc seizures occur anytime during the 8-week baseline phase of the study. * females must agree to acceptable form of birth control. exclusion criteria: * a history of partial seizures or interictal expression of partial seizures as evidenced by electroencephalogram. * have lennox-gastaut syndrome. * currently using or has previously used the drug being studied. * is abusing alcohol and/or other substance(s). * has taken an investigational drug during the 30 days prior to the study or plans to take an investigational drug anytime during the study. * is receiving chronic (long-term) treatment with any medication that could influence seizure control. * follows the ketogenic diet. * is planning surgery to control seizures during the study. * is suffering from acute or progressive neurological disease, severe psychiatric disease, or severe mental abnormality. * has any clinically significant heart, kidney, or liver condition, or a condition that affects how drugs are absorbed, distributed, metabolized, or removed from the body.

Keywords: pgtc lamotrigine epilepsy seizures primary generalized tonic-clonic
thyroid gland dysfunction and vitamin d polymorphism in keratoconus

Conditions: Keratoconus

Summary: this prospective study the thyroid gland dysfunction and vitamin d receptor polymorphism in keratoconus patients

this is a prospective observational study in which blood samples are collected from keratoconus patients looking for thyroid dysfunction and vitamin d levels in the serum and assessing the vitamin d receptor polymorphism in comparison to healthy control.

Eligibility criteria:
inclusion criteria: * keratoconus patients without previously diagnosed thyroid disorder in comparison to healthy control without known systemic disease and with normal cornea who were selected from candidates of refractive surgery with normal topography exclusion criteria: * patients who could not provide informed consent or the necessary samples for any reason, patients with associated other ophthalmic pathologies or systemic disorders were excluded from the study

Keywords: thyroid dysfunction vitamin d polymorphism keratoconus
the impact of legumes vs corn-soy flour on environmental enteric dysfunction in rural malawian children 1-3 year olds

Conditions: Environmental Enteropathy

Summary: to determine if 12 months of legume-based complementary foods is effective in reducing or reversing eed and linear growth faltering in a cohort of malawian children, aged 12-35 months to see if these improvements are correlated with specific changes in the enteric microbiome.


Eligibility criteria:
inclusion criteria: * children residing in catchment area of limela, machinga district and n tenda (chikwawa district), malawi * aged 12-35 months * youngest eligible child in each household exclusion criteria:unable to drink 20 ml of sugar water * demonstrating evidence of severe acute malnutrition, whz \< or = -3, presence of bi-pedal pitting edema * apparent need for acute medical treatment for an illness or injury * caregiver refusal to participate and return for 3, 6 and 12 month follow-ups
12 weeks of resistance band exercise impacts on adiposity, hormones, and blood pressure in postmenopausal women

Conditions: Hypertension; Hormone Disturbance; Adiposity

Summary: the purpose of this study was to examine the impacts of a 12-week resistance band exercise program on body composition, aging-related hormones, and blood pressure in postmenopausal women with stage 1 hypertension. twenty postmenopausal women with hypertension participated in this study. participants were randomly allocated into the resistance band training group (ex, n = 10) or the control group (con, n = 10). the ex group performed a resistance band exercise training program at jump rope training program at 40-70% of their heart rate reserve (hrr) 5 days/week for 12 weeks (sessions 60 minutes in duration). the con group did not participate in any exercise, dietary, or behavioral intervention. body composition, aging-related hormones (growth hormone, insulin-like growth factor 1, dehydroepiandrosterone, and estradiol), and blood pressure were measured before and after the 12-weeks study.


Eligibility criteria:
inclusion criteria: * postmenopausal * hypertensive * sedentary (no regular exercise training or physical activity within previous year) exclusion criteria: * premenopausal * renal, pulmonary, and/or heart disease * regularly physically active

Keywords: postmenopausal exercise
a study of the early activity of ixekizumab (ly2439821) in moderate-to-severe psoriasis

Conditions: Psoriasis

Summary: to detect onset of activity of ixekizumab in participants with moderate-to-severe plaque psoriasis and to document the same using sequential photographic images.


Eligibility criteria:
inclusion criteria: * present with chronic moderate-to-severe plaque psoriasis based on a confirmed (by a dermatologist) diagnosis of chronic plaque psoriasis for at least 6 months prior to baseline * active psoriatic skin lesions of plaque psoriasis (ps) * are a candidate for phototherapy and/or systemic therapy * men must agree to use a reliable method of birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment * women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment exclusion criteria: * are unable to commit to the photography schedule for the duration of the study * have participated in any study with interleukin 17 (il-17) or (il-23) antagonists, including ixekizumab * serious disorder or illness other than psoriasis * serious infection within the last 3 months * breastfeeding or nursing (lactating) women
is rebamipide effective on the healing of iatrogenic gastric ulcer after endoscopic mucosal resection?

Conditions: Stomach Ulcer

Summary: treatment strategy of post endoscopic submucosal dissection (esd) ulcer is not yet conclusive. rebamipide is a mucosal protective agent widely used in east asia and has good effect on quality of ulcer healing (qouh). the investigators will conduct this randomized controlled study to assess the effect of a combination therapy of rebamipide and proton pump inhibitor (ppi) on post esd ulcer healing.


Eligibility criteria:
inclusion criteria: * patients underwent esd for gastric adenoma or cancer exclusion criteria: * subjects with previous gastric surgery * subjects taking aspirin, anticoagulant, or antiplatelet agent * subjects having malignancy except gastric cancer * pregnant or breast-feeding women

Keywords: rebamipide gastric ulcer healing rate iatrogenic gastric ulcer after endoscopic submucosal dissection
reflexology on seizure frequency, fatigue, stress and sleep quality in epilepsy patients

Conditions: Reflexology; Epilepsy; Fatigue; Stress

Summary: epilepsy is among the diseases that cause loss of neurological abilities regardless of any trauma. reflexology is one of the complementary therapies based on activating the body's self-healing power through special hand techniques applied to the feet. it is known that there are positive changes in seizure frequency, fatigue, stress and sleep quality in epilepsy patients after reflexology. this study will be conducted to determine the effect of reflexology on seizure frequency, fatigue, stress and sleep quality in epilepsy patients.

individual interviews were conducted with epilepsy patients who applied to the neurology clinic of a university hospital where the research was conducted, and patients who met the inclusion criteria and agreed to participate in the study will be randomly included in the experiment. patients arriving on the first day of the week will be placed in the experimental group. in the following days, groups will be formed as one day experiment and one day control (monday-experiment, tuesday-control, wednesday-experiment, thursday-control, friday-experiment). data collection tools will be applied to the experimental and control group patients at the beginning and end of the study. only reflexology massage will be applied to the experimental group, and no application will be applied to the control group. data will be collected simultaneously with the control and experimental groups.

Eligibility criteria:
inclusion criteria: * knowing the diagnosis of the disease * having not received reflexology therapy before * being literate in turkish * conscious open, * able to communicate verbally, * being 18 years or older exclusion criteria: * pain starts while doing massage, * having an infection, * high fever, * having clot problems in the leg veins, * having an acute (newly developing) disease (heart attack, fainting, etc.), * wounds in the application area, * patients in the first 3 months of pregnancy. * paraplegia or thrombosis * leg varicose veins or foot disease (open wound or fracture on the foot) * diagnosis of psychiatric disorder or dementia
resting energy expenditure and substrate consumption in cardiac arrest patients under target temperature management

Conditions: Targeted Temperature Management; Cardiac Arrest; Resting Energy Expenditure; Nutrition

Summary: this study is a single-center, prospective, observational study. according to the sample size formula, an estimated 40 cases should be collected, all of whom are from the emergency intensive care unit. after successful cardiopulmonary resuscitation, the enrolled patients will be transferred to the emergency intensive care unit for further standardized target temperature management (ttm). they will be divided into 33 ° c hypothermia group and 36 ° c hypothermia group according to the patient's core body temperature. the baseline data of the patients will be collected at the beginning. after admission to the hospital, they were fasted within 24 hours to reach the target temperature, and then 20kcal/kg/d parenteral nutrition will be given. at selected time points (t0: the initial time point before ttm; t1: the core temperature was reduced to 33 ° c or 36 ° c; t2-t4: 33 ° c or 36 ° c was maintained for 24h, 48h, 72h; t5: the end of rewarming; tend: the last ree measurement before discharge or death) , various observation indicators will be collected, including resting energy expenditure (ree), glucose oxidation rate, fat oxidation rate, protein oxidation rate, and metabolism of three major nutrients proportion. neurological outcomes were followed up 28 days after onset according to the cerebral performance categories (cpc) score.


Eligibility criteria:
inclusion criteria: * be admitted to the emergency department of beijing chao-yang hospital, capital medical university; * successfully resuscitated, and are unconscious after restoration of spontaneous circulation (rosc); * be admitted to the intensive care unit (icu) for advanced life support such as endotracheal intubation after restoration of spontaneous circulation (rosc); * accepted target temperature management (ttm) therapy after restoration of spontaneous circulation (rosc); exclusion criteria: * age \> 18 years old； * incomplete clinical data and loss of follow-up; * traumatic brain injury or cerebrovascular accident revealed by computed tomography (ct)； * severe metabolic abnormalities are known: cachexia, thyroid dysfunction, and cancer； * indirect calorimetry measurement is not possible such as sustained oxygen concentration \> 70%； * there were no signs of resuscitation at the time of admission；
normal pressure hydrocephalus (nph) registry

Conditions: Normal Pressure Hydrocephalus

Summary: the overall aim of the registry is to develop a longitudinal, observational database that is focused on adult patients with normal pressure hydrocephalus (nph) that can be used as a source of clinical information for individual surgeons, as well as a national data repository for scientific inquiry and publications.

this is a prospective, multi-center, observational database to collect data on the characteristics, management practices, and patient outcomes of nph patients. it will be offered to a geographically representative group of u.s. physicians who will enroll nph patients. the physician makes his/her own clinical decisions; thus, the data captured provides current practice patterns related to diagnosis, management, and results. the registry may also assist physicians in patient follow-up and certain practice management tasks. the data collected will serve to inform the medical community on optimal care for this patient population

Eligibility criteria:
inclusion criteria: * patient meets the diagnosis criteria for normal pressure hydrocephalus * patient is a candidate for a hydrocephalus shunt system, per the discretion of the investigator * patient or legal representative has signed an informed consent form. competency to sign the consent form will be left up to the discretion of the investigator exclusion criteria: * patient is under the age of 18 years * patient has a known contraindication for a shunt * patient has an expected life span of less than 24 months * patient has an unwillingness or inability to return for required follow-up visits

Keywords: nph hydrocephalus
pk and safety of hcp1303 and co-administration of hgp1201, hip1402 under fed condition in healthy male volunteers

Conditions: Erectile Dysfunction; Prostatic Hyperplasia

Summary: to investigate the pharmacokinetic properties and safety after administration of hcp1303 and co-administration of hgp1201, hip1402 under fed condition in healthy male volunteers

the purpose of this study is to investigate the pharmacokinetic properties and safety after administration of hcp1303 capsule and co-administration of hgp1201 tablet, hip1402 capsule under fed condition in healthy male volunteers

Eligibility criteria:
inclusion criteria: 1. healthy male volunteer, age 19\~55 years 2. the result of body mass index(bmi) is not less than 19 kg/m2 , no more than 27 kg/m2 3. subject who has the ability to comprehend the study objectives, contents and the property of the study drug before participating in the trial 4. subject who has the ability and willingness to participate the whole period of trial exclusion criteria: 1. presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in kidney, liver, cardiovascular system, respiratory system, endocrine system, or neuropsychiatric system. 2. history of relevant drug allergies or clinically significant hypersensitivity reaction. 3. glomerular filtration rate is under 60ml/min which is calculated by serum creatinine value. 4. liver enzyme (ast, alt) level exceeds the maximum normal range more than one and a half times. 5. sbp: lower than 90mmhg or higher than 150mmhg, dbp: lower than 60mmhg or higher than 100mmhg 6. subjects who judged ineligible by the investigator.
acoart rf closure:radiofrequency for varicose veins of lower extremity in china

Conditions: Varicose Veins of Lower Limb

Summary: the purpose of the rct trial is to determine whether endovenous radiofrequency closure catheter and endovenous radiofrequency closure generator is not inferior to closurefast™ and closurerfg™ in treating varicose veins of lower extremity.

this trial is a prospective, multi-center, 1:1 randomized using endovenous radiofrequency closure catheter and endovenous radiofrequency closure generator versus closurefast™ and closurerfg™ to treat varicose veins of lower extremity. and parimary endpoint is complete closure rate of great saphenous vein at 6 months post-procedure.

Eligibility criteria:
inclusion criteria: * 18 to 80 years of age * patients clinically diagnosed as primary varicose great saphenous veins of lower extremity. and unilateral superficial varicose veins of lower extremity will be treated in this procedure. * patients with ceap classification as c2-c5. * voluntarily participate in this study and sign the informed consent form exclusion criteria: * patients with target vein diameter \ 15mm. * the distance between the anterior wall of the vessel and the skin of the target vein under ultrasound is less than 0.5cm. * patients with aneurysmal dilation at the saphenous femoral junction. * patients with venous aneurysm (defined as venous hemangioma with a diameter greater than or equal to 2 times the diameter of the adjacent vein). * thrombosis or thrombophlebitis in the trunk of great saphenous vein. * the great saphenous vein is so tortuous that radiofrequency closure catheter cannot cross the vein trunk. * patients with target diseased vessels who have received surgical treatment in the past. * patients with deep venous thrombosis or a history of pulmonary embolism. * patients with active implants such as pacemakers or icd. * patients with severe hepatic and renal dysfunction (alt \> normal upper limit 3 times; creatinine \> 225umol/l). * patients who are contraindications to anesthesia. * patients with secondary varicose veins caused by deep venous thrombosis syndrome, cockett syndrome (iliac vein compression syndrome), kt syndrome (venous malformation hypertrophy syndrome), arteriovenous fistula, etc. * any serious or uncontrollable systemic disease (including uncontrolled hypertension, diabetes, active bleeding signs or severe coagulation disorders, etc.). * patients with diseases that may cause difficulties in treatment and evaluation (such as malignant tumors, acute infectious diseases, septicemia, general intolerability of surgery, life expectancy less than 12 months, etc.). * pregnant and lactating women, or those who had a planned birth during the study period. * patients who have participated in clinical trials of other drugs or medical devices in the past 3 months. * according to the judgement of the investigator, other situations that are not suitable for enrollment.

Keywords: varicose veins of lower limb radiofrequency ablation endovenous closure